StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for CTNM yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-19 | $12.70 | $12.76 | +0.47% | 0.1M |
| 05-20 | $12.78 | $13.39 | +4.77% | 0.2M |
| 05-21 | $13.40 | $14.37 | +7.24% | 0.2M |
| 05-22 | $14.35 | $13.86 | -3.41% | 0.2M |
| 05-26 | $13.85 | $13.63 | -1.59% | 0.1M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2024 2024-12-31 | Q3 2024 2024-09-30 | Q2 2024 2024-06-30 | Annual 2023 2023-12-31 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $50.00M |
Operating Income | $-50.89M | $-33.85M | $-20.87M | $16.08M |
Net Income | $-42.26M | $-27.69M | $-9.01M | $22.72M |
EPS (Diluted) | $-2.18 | $-1.61 | $-1.35 | $0.08 |
Total Assets | $212.85M | $216.03M | $221.35M | $130.39M |
Total Liabilities | $14.78M | $5.81M | $3.85M | $5.70M |
Cash & Equivalents | $21.94M | $40.89M | $77.23M | $15.53M |
Free Cash Flow OCF − CapEx | $-33.36M | $-22.99M | $-16.74M | $18.93M |
Shares Outstanding | 19.35M | 17.18M | 12.86M | 2.35M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.